Based on the analysis of Histogen's profitability, liquidity, and operating efficiency, Histogen is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Histogen's Common Stock Shares Outstanding is very stable compared to the past year. As of the 31st of January 2025, Liabilities And Stockholders Equity is likely to grow to about 33 M, while Short and Long Term Debt Total is likely to drop about 3.9 M. Key indicators impacting Histogen's financial strength include:
The financial analysis of Histogen is a critical element in measuring its lifeblood. Investors should not minimize Histogen's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(14.95 Million)
Histogen
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Operating Cycle
Cash Conversion Cycle
Sale Purchase Of Stock
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Change To Inventory
Net Borrowings
Change To Account Receivables
Change To Operating Activities
Change To Netincome
Change To Liabilities
Investments
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Other Assets
Long Term Debt
Capital Surpluse
Property Plant Equipment
Current Deferred Revenue
Net Receivables
Other Liab
Net Tangible Assets
Inventory
Capital Lease Obligations
Net Invested Capital
Capital Stock
Net Working Capital
Short Term Debt
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Interest Income
Total Revenue
Gross Profit
Net Income Applicable To Common Shares
Minority Interest
Net Interest Income
Net Income From Continuing Ops
Cost Of Revenue
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Histogen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Histogen's financial statements are interrelated, with each one affecting the others. For example, an increase in Histogen's assets may result in an increase in income on the income statement.
Histogen competes with Virax Biolabs, Artelo Biosciences, Curis, Senti Biosciences, and Cingulate. Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California. Histogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Histogen's current stock value. Our valuation model uses many indicators to compare Histogen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Histogen competition to find correlations between indicators driving Histogen's intrinsic value. More Info.
Histogen is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Histogen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Histogen's earnings, one of the primary drivers of an investment's value.
Histogen Systematic Risk
Histogen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Histogen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty-five with a total number of output elements of sixteen. The Beta measures systematic risk based on how returns on Histogen correlated with the market. If Beta is less than 0 Histogen generally moves in the opposite direction as compared to the market. If Histogen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Histogen is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Histogen is generally in the same direction as the market. If Beta > 1 Histogen moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Histogen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Histogen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Histogen growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Histogen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Histogen. We use our internally-developed statistical techniques to arrive at the intrinsic value of Histogen based on widely used predictive technical indicators. In general, we focus on analyzing Histogen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Histogen's daily price indicators and compare them against related drivers.
When determining whether Histogen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Histogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Histogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Histogen Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Histogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Histogen Stock, please use our How to Invest in Histogen guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Histogen. If investors know Histogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Histogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.81)
Revenue Per Share
0.004
Return On Assets
(0.54)
Return On Equity
(1.20)
The market value of Histogen is measured differently than its book value, which is the value of Histogen that is recorded on the company's balance sheet. Investors also form their own opinion of Histogen's value that differs from its market value or its book value, called intrinsic value, which is Histogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Histogen's market value can be influenced by many factors that don't directly affect Histogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Histogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Histogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Histogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.